Browse Category

NASDAQ:AMC News 9 December 2025 - 3 February 2026

2026 Golden Globe Nominations: ‘One Battle After Another’ Leads as Netflix–Warner Battle Jolts Hollywood Movie Stocks

2026 Golden Globe Nominations: ‘One Battle After Another’ Leads as Netflix–Warner Battle Jolts Hollywood Movie Stocks

Published December 9, 2025 The first big awards salvo of 2026 has landed — and it hits right in the middle of Hollywood’s most dramatic corporate soap opera in years. On Monday, December 8, the Hollywood Foreign Press Association (HFPA) announced nominations for the 83rd Golden Globe Awards, with Paul Thomas Anderson’s dark comedy–thriller One Battle After Another topping the field with ninenods, followed by Sentimental Value and Sinners as major contenders. Reuters+1 The ceremony will take place on January 11, 2026, airing live on CBS and streaming on Paramount+, once again hosted by comedian Nikki Glaser. Golden Globes+1 At the same time, Netflix, Warner Bros. Discovery and Paramount are locked in a high‑stakes takeover fight that

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop